Literature DB >> 28417458

Resistin causes G1 arrest in colon cancer cells through upregulation of SOCS3.

Snahlata Singh1, Surbhi Chouhan1, Naoshad Mohammad1, Manoj Kumar Bhat1.   

Abstract

Resistin, a proinflammatory cytokine, is elevated in a number of pathological disorders, including cancer. The serum resistin level in colon cancer patients is elevated and correlates with tumor grade. However, the implications of increased resistin on colon cancer cells remain unclear. In the present study, we find that resistin binds to TLR4 on colon cancer cell membrane and initiates TLR4-MyD88-dependent activation of ERK. In addition, the upregulation of SOCS3 by ERK downregulates the JAK2/TAT3 pathway and causes the arrest of cells in G1 phase. Interestingly, we observe that resistin-exposed cells survive 5-fluorouracil treatment because of a decrease in drug uptake due to the arrest of cells in G1 phase.
© 2017 Federation of European Biochemical Societies.

Entities:  

Keywords:  SOCS3; TLR4; colon cancer; resistin

Mesh:

Substances:

Year:  2017        PMID: 28417458     DOI: 10.1002/1873-3468.12655

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  25 in total

Review 1.  Resistin: An inflammatory cytokine with multi-faceted roles in cancer.

Authors:  Sarabjeet Kour Sudan; Sachin Kumar Deshmukh; Teja Poosarla; Nicolette Paolaungthong Holliday; Donna Lynn Dyess; Ajay Pratap Singh; Seema Singh
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-08-19       Impact factor: 10.680

2.  Circular RNA circ_HN1 facilitates gastric cancer progression through modulation of the miR-302b-3p/ROCK2 axis.

Authors:  Ding Wang; Xiaohui Jiang; Yi Liu; Guangxin Cao; Xueliang Zhang; Yuting Kuang
Journal:  Mol Cell Biochem       Date:  2020-09-19       Impact factor: 3.396

3.  [Role of cytokine signal suppressor 3 in the regulatory mechanism of colon cancer invasion and proliferation].

Authors:  Zhu Hong; Xipeng Zhang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-01-30

4.  Long non-coding RNA KCNQ1OT1 up-regulates CTNND1 by sponging miR-329-3p to induce the proliferation, migration, invasion, and inhibit apoptosis of colorectal cancer cells.

Authors:  Xing Liu; Yexiang Zhang; Yan Wang; Chao Bian; Fengji Wang
Journal:  Cancer Cell Int       Date:  2020-07-24       Impact factor: 5.722

5.  Cell Death by Gallotannin Is Associated with Inhibition of the JAK/STAT Pathway in Human Colon Cancer Cells.

Authors:  Marwa Houssein; Widian Abi Saab; Mahmoud Khalil; Hala Khalife; Maamoun Fatfat
Journal:  Curr Ther Res Clin Exp       Date:  2020-06-13

6.  Novel oncogenic and chemoresistance-inducing functions of resistin in ovarian cancer cells require miRNAs-mediated induction of epithelial-to-mesenchymal transition.

Authors:  Ling Qiu; Guo-Feng Zhang; Lei Yu; Hong-Yong Wang; Xiao-Jing Jia; Tie-Jun Wang
Journal:  Sci Rep       Date:  2018-08-21       Impact factor: 4.379

7.  Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9).

Authors:  Dipti Athavale; Surbhi Chouhan; Vimal Pandey; Shyamananda Singh Mayengbam; Snahlata Singh; Manoj Kumar Bhat
Journal:  Cancer Metab       Date:  2018-10-25

8.  lncRNA FOXD2-AS1 promotes hemangioma progression through the miR-324-3p/PDRG1 pathway.

Authors:  Tiancheng Zhao; Jiayu Zhang; Cong Ye; Leilei Tian; Yezhou Li
Journal:  Cancer Cell Int       Date:  2020-05-24       Impact factor: 5.722

9.  Impacts of RETN genetic polymorphism on breast cancer development.

Authors:  Chao-Qun Wang; Chih-Hsin Tang; Huey-En Tzeng; Lulu Jin; Jin Zhao; Le Kang; Yan Wang; Gui-Nv Hu; Bi-Fei Huang; Xiaoni Li; Yong-Ming Zhao; Chen-Ming Su; Hong-Chuan Jin
Journal:  J Cancer       Date:  2020-02-20       Impact factor: 4.207

10.  Resistin enhances angiogenesis in osteosarcoma via the MAPK signaling pathway.

Authors:  Hsiao-Chi Tsai; Shih-Ping Cheng; Chien-Kuo Han; Yuan-Li Huang; Shih-Wei Wang; Jie-Jen Lee; Cheng-Ta Lai; Yi-Chin Fong; Chih-Hsin Tang
Journal:  Aging (Albany NY)       Date:  2019-11-13       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.